Profiling autoantibodies using seromics can provide a deeper understanding of a patient’s immune state, offering great promise for assessing disease and predicting treatment response. Seromics plays a valuable role in a multi-omics approach, complementing genomics, transcriptomics, and proteomics.

Autoantibody biomarkers identified and validated using Sengenics protein arrays have shown utility in a range of high-value applications—from early disease detection and patient stratification to treatment monitoring and prediction of treatment outcomes and immune-related adverse events (irAE).

Learn more about key applications for Sengenics technology and services.